STOCK TITAN

22Nd Century - XXII STOCK NEWS

Welcome to our dedicated page for 22Nd Century news (Ticker: XXII), a resource for investors and traders seeking the latest updates and insights on 22Nd Century stock.

22nd Century Group (NASDAQ: XXII) pioneers plant-based solutions for tobacco harm reduction through advanced biotechnology. This news hub provides investors and stakeholders with essential updates on regulatory milestones, product innovations, and operational developments central to the company's mission of reducing nicotine addiction.

Access authoritative coverage of FDA communications, VLN product advancements, and manufacturing capacity updates. Our curated collection includes earnings reports, patent filings, and scientific research collaborations that demonstrate 22nd Century's leadership in developing reduced-nicotine tobacco products.

Key updates feature the company's Modified Risk Tobacco Product authorization, progress in international market expansion, and innovations in nicotine biosynthesis control. Regular updates ensure informed tracking of this biotechnology firm's unique position at the intersection of public health and commercial tobacco production.

Bookmark this page for streamlined access to verified corporate announcements and analysis-free reporting on 22nd Century's progress in redefining tobacco consumption through science-driven solutions.

Rhea-AI Summary

22nd Century Group announced that its VP of Regulatory Science, John Pritchard, will join the FDLI Tobacco and Nicotine Products Committee. This committee focuses on tobacco product regulation and aims to advance public health policy by discussing the FDA's proposed nicotine cap for cigarettes. The FDA's plan seeks to lower nicotine to 0.5 mg per gram, deemed minimally addictive. 22nd Century is confident in the final stages of its Modified Risk Tobacco Product application for its VLN® cigarettes, which contain 95% less nicotine than traditional cigarettes, potentially aiding millions in quitting smoking.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.47%
Tags
none
-
Rhea-AI Summary

22nd Century Group, a leader in plant-based biotechnology, announced its confidence in the FDA's reduced nicotine mandate, supported by four former FDA commissioners. Their VLN® King and VLN® Menthol King products contain 95% less nicotine than traditional cigarettes, making them compliant with the FDA's proposed nicotine cap. A Modified Risk Tobacco Product (MRTP) designation for VLN® is anticipated, potentially allowing the company to promote its low nicotine levels. The company believes this could significantly impact public health by helping over five million people quit smoking in the first year alone.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.78%
Tags
none
-
Rhea-AI Summary

22nd Century Group (XXII) congratulates Xavier Becerra on his appointment as Secretary of HHS, believing it could revitalize the FDA's plan to regulate nicotine levels in cigarettes. Becerra’s advocacy for a nicotine cap aligns with 22nd Century's mission to reduce harm from smoking. The company highlights that its VLN® product, engineered to contain 95% less nicotine, complies with proposed regulations. The FDA is anticipated to grant a Modified Risk Tobacco Product designation for VLN®, enabling the company to market it effectively to help smokers reduce nicotine exposure.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.61%
Tags
none
Rhea-AI Summary

22nd Century Group (NYSE American: XXII) announced a successful cash exercise of warrants resulting in $3.7 million in additional net proceeds, totaling $11.8 million. The completion of this transaction eliminates all outstanding warrants, thereby enhancing its balance sheet. CEO James A. Mish expressed intentions to utilize these funds for growth opportunities in the tobacco and hemp/cannabis sectors, particularly in sales and licensing, contingent on acquiring Modified Risk Tobacco Products (MRTP) authorization for its Very Low Nicotine (VLN) cigarettes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.96%
Tags
none
-
Rhea-AI Summary

22nd Century Group (XXII) reported steady net sales of $7.3 million for Q4 2020, consistent year-over-year, and a full-year revenue increase of 8.8% to $28.1 million. The gross profit rose significantly, with a margin improvement of 500 basis points. Net loss for Q4 was $(6.4) million, slightly up from the prior year. However, full-year net loss improved by $6.8 million to $(19.7) million. The company is poised to launch its VLN® cigarettes following MRTP authorization from the FDA, aiming to capitalize on new partnerships in the tobacco and hemp/cannabis industries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.62%
Tags
-
Rhea-AI Summary

22nd Century Group, Inc. (NYSE American: XXII) has announced its participation in three investor conferences throughout March 2021. The events include the DA Davidson 4th Annual Consumer Growth Conference on March 11, the 33rd Annual Roth Conference from March 15-17, and the Investor Summit Virtual Conference from March 23-25. Investors can request one-on-one meetings with the management team via conference hosts. The company focuses on tobacco harm reduction and hemp/cannabis research, emphasizing reduced nicotine content tobacco products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.09%
Tags
conferences
Rhea-AI Summary

22nd Century Group, Inc. (NYSE American: XXII) announced it received net proceeds of $8.1 million from warrants exercised in February and March 2021, enhancing its balance sheet. The company expects an additional $3.7 million if remaining warrants are exercised. CEO James A. Mish stated that the capital will support operations, strategy, and growth initiatives across tobacco and hemp/cannabis sectors. The funds will aid in acquiring Modified Risk Tobacco Products (MRTP) authorization and support research in hemp/cannabis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.74%
Tags
none
-
Rhea-AI Summary

22nd Century Group, Inc. (XXII) has secured an exclusive agreement with CannaMetrix, LLC to utilize their proprietary CannaMetrix EC50Array™ technology. This partnership aims to expedite the commercialization of innovative hemp/cannabis plant lines, reducing development time from over ten years to just two. The company has now established four out of five key partnerships needed for the cannabinoid value chain, focusing on plant profiling, biotechnology, cultivation, and extraction. This move aligns with its strategy to advance the hemp/cannabis industry significantly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.94%
Tags
none
-
Rhea-AI Summary

22nd Century Group (NYSE American: XXII) will host a live webcast on March 11, 2020, at 8:00 a.m. EST to discuss its fourth quarter and full-year 2020 results. The company will issue its results at 7:00 a.m. the same day. CEO James A. Mish and other executives will provide insights on 2020 performance, future milestones, and market opportunities in the $800 billion tobacco and hemp/cannabis sectors. An interactive Q&A will follow the presentation. Access to the webcast is available on the company’s investor relations page.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.75%
Tags
conferences
Rhea-AI Summary

22nd Century Group is focused on tobacco harm reduction and hemp/cannabis research. The company reported a 343% stock increase to $3.82 as of February 23, 2021, highlighting its MRTP application for VLN® reduced nicotine cigarettes, which if approved, could position it as the only company with a MRTP designation for combustible cigarettes. The company is also advancing its cannabis strategy by developing new hemp varieties through molecular breeding technology, capitalizing on a projected $39.1 billion North American cannabis market by 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.71%
Tags
none
22Nd Century

NYSE:XXII

XXII Rankings

XXII Stock Data

1.84M
1.82M
41.08%
10.28%
13.02%
Tobacco
Cigarettes
Link
United States
WILLIAMSVILLE